natgillin/translations-raw huggingface dataset:
It sticks to the surface of a type of white blood cell called “B-Lymphocyte”. 
Veže se na površino vrste belih krvnih celic, ki jih imenujemo limfociti B. Ko se rituksimab veže na njihovo površino, odmrejo.
In a prospective, open label, international, multi-centre, phase III trial, 465 patients with relapsed/refractory follicular lymphoma were randomised in a first step to induction therapy with either CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone; n=231) or MabThera plus CHOP (R-CHOP, n=234). 
pri katerih so se folikularni limfomi ponovili ali se niso odzvali na zdravljenje, randomiziranih v prvi del indukcijskega zdravljenja s CHOP (ciklofosfamid, doksorubicin, vinkristin, prednizolon, n = 231) ali zdravljenje z zdravilom MabThera in CHOP (R-CHOP, n = 234).
For each term, the frequency count was based on reactions of all grades (from mild to severe), except for terms marked with "+" 
Pri vsakem izrazu so pri določitvi pogostnosti upoštevali neželene učinke vseh stopenj (od blage do hude), razen za izraze, označene s "+", kjer so pri določitvi pogostnosti upoštevali le hude neželene učinke (≥ 3. stopnja po lestvici skupnih meril toksičnosti Nacionalnega inštituta za raka
The recommended dose of MabThera used as a maintenance treatment for patients with previously untreated follicular lymphoma who have responded to induction treatment is: 375 mg/m2 body surface area once every 2 months (starting 2 months after the last dose of induction therapy) until disease progression or for a maximum period of two years (12 infusions in total). 
Priporočeni odmerek zdravila MabThera za vzdrževalno zdravljenje bolnikov s predhodno nezdravljenimi folikularnimi limfomi, ki so se odzvali na indukcijsko zdravljenje, je: 375 mg/m2 telesne površine enkrat na 2 meseca (z začetkom 2 meseca po zadnjem odmerku indukcijskega zdravljenja) do napredovanja bolezni ali največ dve leti (skupaj 12 infuzij).
Angina pectoris, cardiac arrhythmias such as atrial flutter and fibrillation, heart failure and/or myocardial infarction have occurred in patients treated with MabThera. 
Pri bolnikih, zdravljenih z zdravilom MabThera, so se pojavili angina pektoris, srčne aritmije, kot sta atrijska undulacija in fibrilacija, srčno popuščanje in/ali miokardni infarkt.
Most common local cutaneous reactions were injection site erythema (26%), injection site pain (16%), and injection site swelling (5%).Two patients in SAWYER trial who experienced Grade 3 local cutaneous reactions (injection site erythema, injection site pain and injection site swelling). 
Najpogostejše lokalne kožne reakcije so bile eritem na mestu injiciranja (26 %), bolečina na mestu injiciranja (16 %) in otekanje na mestu injiciranja (5 %).
MabThera was administered as an intravenous infusion at a first-cycle dose of 375 mg/m2 increased to 500 mg/m2 each cycle for 5 doses in combination with fludarabine and cyclophosphamide in CLL patients. 
Zdravilo MabThera so bolnikom s KLL dajali v obliki intravenske infuzije v odmerku 375 mg/m2 telesne površine v prvem ciklu zdravljenja, odmerek pa se je v naslednjih 5 ciklih zdravljenja povečal na 500 mg/m2 telesne površine (v kombinaciji s fludarabinom in ciklofosfamidom).
Table 10b First-line treatment of chronic lymphocytic leukaemia Hazard ratios of progression-free survival according to Binet stage (ITT) - 48.1 months median observation time Progression-free survival (PFS) 
Razmerja ogroženosti za preživetje brez napredovanja bolezni glede na stopnjo po Binetu (ITT) - mediana opazovanja 48,1 meseca Preživetje brez napredovanja bolezni (PFS)
• A complex of symptoms occurring within a few weeks of an infusion of MabThera including allergic like reactions such as rash, itching, joint pain, swollen lymph glands and fever 
Zelo redki neželeni učinki (pojavijo se lahko pri 1 od 10.000 bolnikov): · skupek simptomov, ki se pojavi v nekaj tednih po prejemu infuzije zdravila MabThera, in vključuje alergijske reakcije, kot so kožni izpuščaji, srbenje, bolečine v sklepih, otekle bezgavke in zvišano telesno temperaturo,
• bald spots on the scalp, chills, headache 
· plešasti predeli na lasišču, mrzlica, glavobol
Very rare side effects (may affect up to 1 in 10, 000 people): 
Zelo redki neželeni učinki (pojavijo se lahko pri 1 od 10.000 bolnikov):
Co-administration with MabThera did not appear to have an effect on the pharmacokinetics of fludarabine or cyclophosphamide. 
Sočasna uporaba zdravila MabThera ni vplivala na farmakokinetiko fludarabina ali ciklofosfamida.
The most frequent ADRs following receipt of MabThera in clinical studies were IRRs (refer to Table 2). 
Najpogostejši neželeni učinki po prejemu zdravila MabThera v kliničnih preskušanjih so bile reakcije,
Local cutaneous reactions were very common in patients receiving MabThera subcutaneous in clinical trials. 
Lokalne kožne reakcije so bile v kliničnih preskušanjih pri prejemnikih podkožne oblike zdravila MabThera pogoste.
In trial SparkThera, no severe administration-related reactions were reported. 
V preskušanju SparkThera niso zabeležili hudih reakcij, povezanih z dajanjem zdravila.
No difference between the R-CHOP and CHOP group was observed in the incidence of other grade 3 and 4 cardiac events including heart failure, myocardial disease and manifestations of coronary artery disease. 
Incidenca preostalih srčnih dogodkov 3. in 4. stopnje (vključno s srčnim popuščanjem, miokardno boleznijo in manifestacijami koronarne bolezni)
Mean change DAS28-ESR -1.97** 
Povprečna sprememba v DAS28-ESR
• being sick (vomiting), diarrhoea, pain in the stomach, irritation or ulcers in the throat and mouth, problems swallowing, constipation, indigestion 
· bruhanje, driska, bolečine v trebuhu, draženje ali razjede v žrelu in ustih, težave s požiranjem,
This medicinal product contains less than 1mmol sodium per dose, i.e. essentially sodium free. 
To zdravilo vsebuje manj kot 1 mmol natrija na odmerek, kar pomeni, da je praktično brez natrija.
MabThera has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. 
Zdravilo MabThera v kombinaciji z metotreksatom zmanjša hitrost napredovanja okvar sklepov, ki jih spremljamo z rentgenskim slikanjem, in izboljša funkcijsko zmogljivost.
The recommended dose of MabThera in combination with chemotherapy for induction treatment of previously untreated or relapsed/refractory patients with follicular lymphoma is: 375 mg/m2 body surface area per cycle, for up to 8 cycles. 
Priporočeni odmerek zdravila MabThera v kombinaciji s kemoterapijo za indukcijsko zdravljenje bolnikov s folikularnimi limfomi, ki se predhodno še niso zdravili ali se na prejšnje zdravljenje niso odzvali ali se jim je bolezen ponovila, je: 375 mg/m2 telesne površine na cikel do 8 ciklov.
3Infusion related reactions (generalized oedema, bronchospasm, wheezing, laryngeal oedema, angioneurotic oedema, generalized pruritus, anaphylaxis, anaphylactoid reaction) 
3reakcije, povezane z infuzijo (generalizirani edem, bronhospazem, piskanje, edem grla,
In CLL patients, co-administration with MabThera did not appear to have an effect on the pharmacokinetics of fludarabine or cyclophosphamide. 
Pri bolnikih s KLL sočasna uporaba zdravila MabThera ni vplivala na farmakokinetiko fludarabina ali ciklofosfamida.
The reactions occurring within 24 hours of the subcutaneous injection consisted primarily of erythema pruritus, rash and injections site reactions such as pain, swelling and redness and were generally of mild or moderate (grade 1 or 2) and transient nature (see section 4.8). 
Te reakcije so se pojavile v 24 urah po podkožnem injiciranju in so obsegale predvsem eritem, srbenje, izpuščaj in reakcije na mestu injiciranja, npr. bolečine, oteklost in pordelost.
Musculo skeletal disorders arthralgia / musculoskeletal pain, osteoarthritis, bursitis 
Bolezni mišično skeletnega sistema in vezivnega tkiva bolečina v sklepu/mišično-skeletna bolečina, osteoartroza,
See the MabThera package leaflet for more information. 
Za več informacij preberite navodilo za uporabo zdravila MabThera.
In the induction of remission clinical trial, 24% of patients in the MabThera group (single course) and 23% of patients in the cyclophosphamide group developed CTC grade 3 or greater neutropenia. 
V kliničnem preskušanju indukcije remisije se je nevtropenija, ki je bila 3. stopnje ali več po CTC, pojavila pri 24 % prejemnikov zdravila MabThera (en cikel) in pri 23 % prejemnikov ciklofosfamida.
Bronchitis 
burzitis
The estimated median terminal elimination half-life of MabThera was 22 days (range, 6.1 to 52 days). 
Ocenjena mediana končnega razpolovnega časa izločanja podkožne oblike zdravila MabThera je bila 29,7 dneva (razpon: od 9,9 do 91,2 dneva).
Table 8 Induction phase: overview of efficacy results for CHOP vs. R-CHOP (31 months median observation time) CHOP R-CHOP p-value Risk Reduction1) 
Indukcijsko zdravljenje: pregled rezultatov učinkovitosti CHOP v primerjavi z R-CHOP (mediana časa opazovanja 31 mesecev)
A two-stage phase III, international, multi-centre, randomised, controlled, open-label trial was conducted in patients with previously untreated follicular lymphoma, to investigate the non-inferiority of the pharmacokinetic profile, together with efficacy and safety of MabThera subcutaneous formulation in combination with CHOP or CVP versus MabThera intravenous formulation in combination with CHOP or CVP. 
Namenjeno je bilo proučitvi neinferiornosti farmakokinetičnega profila ter učinkovitosti in varnosti podkožne oblike zdravila MabThera v kombinaciji s CHOP ali CVP v primerjavi z intravensko obliko zdravila MabThera v kombinaciji s CHOP ali CVP.
Cardiovascular reactions during clinical trials with MabThera monotherapy were reported in 18.8% of patients with the most frequently reported events being hypotension and hypertension. 
O kardiovaskularnih neželenih učinkih so med kliničnimi preskušanji zdravila MabThera kot samostojnega zdravila poročali pri 18,8 % bolnikov.
In patients with non-Hodgkin's lymphoma and CLL, premedication with glucocorticoids should be considered if MabThera is not given in combination with glucocorticoid-containing chemotherapy. 
Če zdravilo MabThera za zdravljenje ne-Hodgkinovega limfoma in kronične limfocitne levkemije ni uporabljeno v kombinaciji s kemoterapijo, ki vključuje glukokortikoid, je treba razmisliti o premedikaciji z glukokortikoidi.
The recommended dosage of MabThera in combination with chemotherapy for previously untreated and relapsed/refractory patients is: MabThera intravenous formulation 375 mg/m2 body surface area administered on day 0 of the first cycle of treatment followed by MabThera subcutaneous formulation injected at a fixed dose of 1600 mg per cycle, on day 1 of each subsequent cycle (in total: 6 cycles). 
Priporočeni odmerek zdravila MabThera v kombinaciji s kemoterapijo pri bolnikih, ki predhodno še niso bili zdravljeni oziroma se na prejšnje zdravljenje niso odzvali ali pa se je bolezen pri njih ponovila, je intravenska oblika zdravila MabThera v odmerku 375 mg/m2 telesne površine, ki ga damo na dan 0 prvega cikla zdravljenja, v naslednjih ciklih zdravljenja pa podkožna oblika zdravila MabThera, ki jo v enotnem odmerku 1600 mg injiciramo 1. dan vsakega nadaljnjega cikla (skupaj 6 ciklov).
• severe skin problems causing blisters that can be life-threatening 
· hude težave s kožo, ki povzročijo mehurje in so lahko smrtno nevarne
MabThera 500 mg concentrate for solution for infusion Each mL contains 10 mg of rituximab. 
MabThera 500 mg koncentrat za raztopino za infundiranje En ml vsebuje 10 mg rituksimaba.
PHARMACEUTICAL FORM Concentrate for solution for infusion. 
Na voljo je v obliki koncentrata za raztopino za infundiranje.
You might get infections more easily during your treatment with MabThera. 
Med zdravljenjem z zdravilom MabThera ste lahko bolj nagnjeni k okužbam.
Patients treated with MabThera in combination with methotrexate had a significantly greater reduction in disease activity score (DAS28) than patients treated with methotrexate alone (Table 12). 
zmanjšanje aktivnosti bolezni (DAS28, Disease Activity Score) pomembno večje kot pri bolnikih, ki so se zdravili samo z metotreksatom (preglednica 12).
Since hypotension may occur during MabThera infusion, consideration should be given to withholding anti-hypertensive medications 12 hours prior to the MabThera infusion. 
Ker se med infuzijo zdravila MabThera lahko pojavi hipotenzija, je treba premisliti o tem, da bi 12 ur pred infuzijo zdravila MabThera bolnik prenehal jemati zdravila proti visokemu krvnemu tlaku.
The study showed statistically significant results of MabThera and low-dose prednisone over standarddose prednisone in achieving CRoff ≥ 2 months at month 24 in PV patients (see Table 18). 
Rezultati Študija je pri doseganju CRoff ³ 2 meseca po 24 mesecih pri bolnikih z navadnim pemfigusom pokazala statistično značilno razliko med shemo zdravila MabThera in majhnega odmerka prednizona ter shemo s standardnim odmerkom prednizona (glejte preglednico 18).
4 see also section infusion-related reactions below. 
Glejte tudi spodnji odstavek o reakcijah, povezanih z infuzijo.
In the pivotal trial, 166 patients with relapsed or chemoresistant low-grade or follicular B cell NHL received 375 mg/m2 of MabThera as an intravenous infusion once weekly for four weeks. 
V ključnem preskušanju je 166 bolnikov, pri katerih se je nizko maligni ne-Hodgkinov limfom ali folikularni B-celični ne-Hodgkinov limfom ponovil ali pa so bili bolniki neodzivni na kemoterapijo, 4 tedne prejemalo po 375 mg/m2 zdravila MabThera v obliki intravenske infuzije enkrat na teden.
FC) for the first-line study (Table 10a and Table 10b) and 552 patients (276 R-FC, 276 FC) for the relapsed/refractory study (Table 11) were analysed for efficacy. 
810 bolnikov (403 R-FC, 407 FC) iz študije pri bolnikih v prvi liniji zdravljenja (preglednici 10a ter 10b) ter 552 bolnikov (276 R-FC, 276 FC) iz študije pri bolnikih, pri katerih se je bolezen ponovila oziroma so bili neodzivni na zdravljenje (preglednica 11).
Skin and subcutaneous tissue disorders pruritus, rash, +alopecia urticaria, sweating, night sweats, +skin disorder severe bullous skin reactions, Stevens-Johns on syndrome toxic epidermal necrolysis (Lyell's syndrome) 7 
znojenje, nočno znojenje, +bolezen kože hude bulozne kožne reakcije, StevensJohnsonov sindrom,
The geometric mean Ctrough (CV%) values at 
Geometrična sredina Ctrough (na 2 meseca) µg/ml
MabThera 1600 mg is used to treat chronic lymphocytic leukaemia -in adults. 
Za kaj uporabljamo zdravilo MabThera Zdravilo MabThera 1600 mg se uporablja za zdravljenje kronične limfocitne levkemije pri odraslih.
Further, a significantly higher proportion of patients achieved MCIDs for these scores (Table 14). 
Poleg tega je značilno večji delež bolnikov dosegel MCID za ti oceni
The serum rituximab Cmax at cycle 7 was similar between the two treatment arms, with geometric mean (CV%) values of 250.63 (19.01) μg/mL and 236.82 (29.41) μg/mL for the intravenous and the subcutaneous formulations respectively, with the resulting geometric mean ratio (Cmax, SC/Cmax, IV) of 0.941 (90% CI: 0.872, 1.015). 
Geometrična sredina (KV %) je bila z intravensko obliko 250,63 (19,01) µg/ml in s podkožno 236,82 (29,41) µg/ml; razmerje geometričnih sredin (Cmax s.c./Cmax i.v.)
Pack of 1 vial. 
V škatli je 1 viala.
Cases of hepatitis B reactivation, including those with a fatal outcome, have been reported in rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis patients receiving MabThera. 
Reaktivacija hepatitisa B Pri bolnikih z granulomatozo s poliangiitisom in mikroskopskim poliangiitisom, ki so zdravilo
MabThera 100 mg concentrate for solution for infusion Each mL contains 10 mg of rituximab. 
MabThera 100 mg koncentrat za raztopino za infundiranje En ml vsebuje 10 mg rituksimaba.
During MabThera maintenance treatment for up to 2 years, leucopoenia (5% vs. 2%, grade 3/4) and neutropenia (10% vs. 4%, grade 3/4) were reported at a higher incidence when compared to observation. 
Incidenca levkopenije in nevtropenije 3. ali 4. stopnje sta bili v skupini, ki je prejemala vzdrževalno zdravljenje z zdravilom MabThera do 2 leti, višja (levkopenija: 5 %, nevtropenija: 10 %) kot v opazovani skupini (levkopenija: 2 %, nevtropenija: 4 %).
IRRs for patients with granulomatosis with polyangiitis, microscopic polyangiitis and pemphigus vulgaris were consistent with those seen for rheumatoid arthritis patients in clinical trials (see section 
V kliničnih preskušanjih so bile z infuzijo povezane reakcije pri bolnikih z granulomatozo s poliangiitisom, mikroskopskim poliangiitisom in navadnim pemfigusom podobne tistim pri bolnikih z revmatoidnim artritisom (glejte poglavje 4.8).
Your doctor or nurse will place the sticker on the syringe before injection. 
Na stekleni viali je nalepka s podatki o zdravilu, ki jo bo zdravnik ali medicinska sestra pred injiciranjem zdravila nalepila na brizgo.
Progression--free survival (PFS) Overall survival 
log-rang p vrednost preživetje brez napredovanja bolezni (PFS) celokupno preživetje
b) Chronic lymphocytic leukaemia 
b) kronične limfocitne levkemije
Other serious ADRs reported include hepatitis B reactivation and PML (see section 4.4. 
Med drugimi resnimi neželenimi učinki so poročali tudi o reaktivaciji virusa hepatitisa B in o PML
CHOP R-CHOP 
Celokupno preživetje (OS) CHOP R-CHOP
In a population pharmacokinetic analysis in 403 follicular lymphoma patients who received subcutaneous and/or intravenous MabThera, single or multiple infusions of MabThera as a single agent or in combination with chemotherapy, the population estimates of nonspecific clearance (CL1), initial specific clearance (CL2) likely contributed by B cells or tumour burden, and central compartment volume of distribution (V1) were 0.194 L/day, 0.535 L/day, and 4.37 L/day, respectively. 
Populacijska ocena nespecifičnega očistka (CL1) je bila 0,194 l/dan, začetnega specifičnega očistka (CL2), h kateremu verjetno pripomorejo celice B ali tumorsko breme, 0,535 l/dan in volumna porazdelitve centralnega razdelka (V1) 4,37 l/dan.
Nervous system disorders paraesthesia, hypoaesthesia, agitation, insomnia, vasodilatation, dizziness, anxiety dysgeusia peripheral neuropathy, facial nerve palsy5 
vazodilatacija, omotica, anksioznost dizgevzija periferna nevropatija, paraliza obraznega živca5
When injected under your skin, it is given in the stomach area, not in other sites of the body, and not into areas of the stomach where the skin is red, bruised, tender, hard or where there are moles or scars. 
Prav tako se ga ne sme injicirati v predele trebuha, kjer je koža pordela, podpluta, občutljiva, trda ali ima znamenja ali brazgotine.
Previously untreated follicular lymphoma 
Vzdrževalno zdravljenje Predhodno nezdravljeni folikularni limfomi
Experience from granulomatosis with polyangiitis and microscopic polyangiitis 
Izkušnje pri granulomatozi s poliangiitisom in mikroskopskem poliangiitisu Indukcija remisije
At 24 months, estimates for overall survival were 68.2 % in the R-CHOP arm compared to 57.4 % in the CHOP arm. A subsequent analysis of the duration of overall survival, carried out with a median follow-up duration of 60 months, confirmed the benefit of R-CHOP over CHOP treatment (p=0.0071), representing a risk reduction of 32 %. 
Nadaljnja analiza trajanja celokupnega preživetja, ki so jo izvedli po medianem sledenju 60 mesecev, je potrdila prednost zdravljenja z R-CHOP pred CHOP (p = 0,0071), kar pomeni zmanjšanje tveganja za dogodke za 32 %.
Complete response (CR/CRu) rate* 48% 67% 53% 67% chi-squared test p value odds ratio (95% CI) 
vrednost p v testu log-rang razmerje ogroženosti (95-% IZ) zmanjšanje tveganja Delež celokupnega odgovora* vrednost p v testu hi-kvadrat razmerje obetov (95-% IZ) Delež popolnega odgovora (CR/CRu)* vrednost p v testu hi-kvadrat razmerje obetov (95-% IZ)
In a multi-centre, single-arm trial, 37 patients with relapsed or chemoresistant, low grade or follicular B cell NHL received 375 mg/m2 of MabThera as intravenous infusion weekly for eight doses. 
V multicentričnem preskušanju brez primerjalne skupine je 37 bolnikov, pri katerih se je nizko maligni ne-Hodgkinov limfom ali folikularni B-celični ne-Hodgkinov limfom ponovil ali pa so bili bolniki neodzivni na kemoterapijo, prejemalo osem odmerkov po 375 mg/m2 zdravila MabThera v obliki intravenske infuzije enkrat na teden.
3Infusion-related reactions (hypertension, nausea, rash, pyrexia, pruritus, urticaria, throat irritation, hot flush, hypotension, rhinitis, rigors, tachycardia, fatigue, oropharyngeal pain, peripheral oedema, erythema) 
pruritus, urtikarija, draženje žrela, vročinski oblivi, hipotenzija, rinitis, okorelost, tahikardija, utrujenost, orofaringealna bolečina, periferni edem, eritem)
Progression-‑ -free survival (PFS) 
Preživetje brez napredovanja bolezni (PFS)
The dose of 1600 mg of MabThera subcutaneous formulation was selected for the Part 2 of the study. 
Za 2. del preskušanja so izbrali 1600-mg odmerek podkožne oblike zdravila Mabthera.
The incidence of treatment-induced/enhanced anti-rHuPH20 antibodies was 8% in the intravenous group compared with 15% in the subcutaneous group, and none of the patients who tested positive for anti-rHuPH20 antibodies tested positive for neutralizing antibodies. 
Incidenca z zdravljenjem povzročenega/okrepljenega nastajanja protiteles proti rHuPH20 (rekombinantni humani hialuronidazi) je bila 8 % v skupini z intravensko obliko zdravila in 15 % v skupini s podkožno obliko zdravila.
• heart problems - such as heart attack, uneven or fast heart rate 
· težave s srcem - na primer srčni infarkt, neredno ali hitro bitje srca · visok ali nizek krvni tlak (nizek krvni tlak zlasti po hitrem vstajanju)
Subsequent doses of MabThera can be infused at an initial rate of 100 mg/h, and increased by 100 mg/h increments at 30 minute intervals, to a maximum of 400 mg/h. 
Nadaljnje odmerke zdravila MabThera lahko dajemo z začetno hitrostjo 100 mg/h, ki jo lahko vsakih
GENERAL CLASSIFICATION FOR SUPPLY Medicinal product subject to medical prescription 
Vzdrževalno zdravljenje: pregled učinkovitosti zdravljenja z zdravilom
The incidence of infusion-related symptoms decreased substantially with subsequent intravenous infusions and is <1% of patients by the eighth cycle of MabThera (containing) treatment. 
Incidenca simptomov in znakov, povezanih z infuzijo, se je z nadaljnjimi intravenskimi infuzijami precej zmanjšala in je bila do osmega cikla zdravljenja z zdravilom MabThera < 1 %.
Rituximab exposure increased dose proportional over the 375 mg/m2 to 800 mg/m2 subcutaneous dose range. 
375 mg/m2 do 800 mg/m2 s.c. povečevala sorazmerno odmerku.
PFS - Progression-Free Survival (proportion with event, disease progression/relapse or death from any cause) a - at 3 month follow-up visit (Part 2) b - at time of final analysis (median follow-up 53 months) 
a v času obiska po 3-mesečnem spremjanju (2. del) b v času končne analize (mediana spremljanja 53 mesecev)
• memory loss, trouble thinking, difficulty walking or sight loss - these may be due to a very rare, 
· poslabšanje spomina, motnje mišljenja, težave s hojo ali izguba vida - lahko so posledica zelo redke, resne okužbe možganov, ki je bila smrtna (imenujemo jo progresivna multifokalna levkoencefalopatija ali PML).
Each vial contains 1600 mg/ 13.4 mL rituximab. 
1 viala vsebuje 1600 mg/13,4 ml rituksimaba.
Vascular disorders Hypertension 
Žilne bolezni hipertenzija napadi rdečice
doses to 203 patients with NHL naive to MabThera, yielded a mean Cmax following the fourth infusion of 486 µg/mL (range, 77.5 to 996.6 µg/mL). 
MabThera prej še niso zdravili in so prejeli po 375 mg/m2 zdravila MabThera z intravensko infuzijo v štirih odmerkih enkrat na teden, je bila 486 µg/ml (od 77,5 do 996,6 µg/ml).
weekly doses. 
100 bolnik-let.
The chemotherapy should be given after MabThera infusion. 
Kemoterapijo dajemo po infuziji zdravila MabThera.